ADC specialist ImmunoGen closing Massachusetts plant, cutting 20 jobs

Antibody-drug conjugates specialist ImmunoGen will close a small plant and lay off 20 workers, shifting all of its production and quality-testing needs to contractors. (National Cancer Institute)

ImmunoGen has decided to turn to contractors for all of its manufacturing needs, a move that will mean a small facility in Massachusetts will close and 20 workers will be let go.

The Waltham, Massachusetts-based specialist in antibody-drug conjugates made the announcement last week when it released its earnings. ImmunoGen said it will move manufacturing and quality testing solely to contractors.

The move, which is expected to save $20 million over five years, will allow it to gain access to external expertise and benefit from “advances in contract manufacturing capacity,” the drugmaker explained.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The company will continue to use its 25-year-old Norwood, Massachusetts, manufacturing and testing facility for the rest of the year, at which point it will close and its 20 workers will be let go.

CEO Mark Enyedy explained in a call with analysts that as the company has shifted away from “broad-based partnerships” for ADC drugs with companies like Roche and Novartis, its capacity needs at Norwood have declined. ImmunoGen technology is used in Roche's cancer drug Kadcyla, for example. 

The decision is also is in line with future needs, Enyedy said, as the company looks toward 2018 revenues of between $60 million and $65 million and operating expenses between $185 million and $190 million. CFO Dave Johnston told analysts the company expects to end 2018 with between $115 million and $120 million of cash and cash equivalents, which with revenues will carry it through the first quarter of 2019, when some important milestones should be realized.


Suggested Articles

Thermo Fisher Scientific's pharma services group is establishing itself as a gene therapy manufacturer with a $1.7 billion cash deal for Brammer Bio.

The FDA is allowing some drugmakers to exceed the level of risk from a probable cancer-causing impurity in losartan for six months.

CDMOs Cambrex and Ajinomoto Bio-Pharma Services upgraded manufacturing plants, Takeda scored an albumin approval via its Shire deal, and more.